Literature DB >> 22395587

Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application.

Khalifa E Sharquie1, Jamal R Al-Rawi, Adil A Noaimi, Haitham M Al-Hassany.   

Abstract

BACKGROUND: Many therapeutic modalities for scabies were available, topical sulfur ointment is a cost-effective and safe therapeutic agent. It is often applied for the whole body for three successive days.
OBJECTIVE: To evaluate their therapeutic regimen of 8% and 10% topical precipitated sulfur in petrolatum ointment for single day, three successive nights or three successive days in management of scabies. PATIENTS AND METHODS: This single-blinded, comparative study was conducted in the Department of Dermatology-Baghdad Teaching Hospital from April 2008 through October 2009. A total of 97 patients with scabies were enrolled in this study. The diagnosis was established on clinical basis. The patients treated with 8% and 10% topical sulfur in petrolatum ointment were divided randomly into three groups: Group A: 33 patients treated for single day (24 hours); Group B: 32 patients treated for three successive nights (from 6 p.m. to 8 p.m. to 6 a.m. to 8 a.m. and bathing every day); and Group C: 32 patients treated for three successive days (bathing every 24 hours). The patients were seen regularly every two weeks for the duration of four weeks.
RESULTS: Study included 58 (59.8%) males and 39 (40.2%) females, with a male to female ratio 1.4:1. The age range of males at presentation from 3 to 64 (26.74±15.98) years, while the females age ranged at presentation from 3 to 60 (24.05±14.53) years of age. At the end of the study, the response to treatment was: Group A, response in 14 (42.4%) patients and no response in 19 (57.6%); Group B, response in 29 (90.6%) patients and no response in 3 (9.4%); and Group C, response in 31 (96.9%) patients and no response in 1 (3.1%). There is significant statistical difference among the response of 3 groups with (P=0.00000011), but no statistically significant difference between the response of Group C and Group B, (P=0.6055). Mild burning sensation and irritating (sulfur) dermatitis were the only side effects of 8% and 10% sulfur. Pruritic rash occurred in Group C mainly, in 11 (34.4%) patients, 8 (25%) in Group B and 4 (12.1%) in Group A, with no significance (P=0.1058). Recurrence or relapse occurred in Group A mainly, with 4 (12.1%) patients, and in Group B, 1 patient, (3.1%), with no recurrence in group C, with significance (P=0.0060).
CONCLUSION: Three successive days and three successive nights of 8% and 10% sulfur ointment were effective regimens with no statistical difference in favor of three successive days, while single-day application was much less effective but with fewer side effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22395587

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  4 in total

Review 1.  The Treatment of Scabies.

Authors:  Corinna Dressler; Stefanie Rosumeck; Cord Sunderkötter; Ricardo Niklas Werner; Alexander Nast
Journal:  Dtsch Arztebl Int       Date:  2016-11-14       Impact factor: 5.594

Review 2.  Therapeutic Potential of Tea Tree Oil for Scabies.

Authors:  Jackson Thomas; Christine F Carson; Greg M Peterson; Shelley F Walton; Kate A Hammer; Mark Naunton; Rachel C Davey; Tim Spelman; Pascale Dettwiller; Greg Kyle; Gabrielle M Cooper; Kavya E Baby
Journal:  Am J Trop Med Hyg       Date:  2016-01-19       Impact factor: 2.345

Review 3.  Mange in Rabbits: An Ectoparasitic Disease with a Zoonotic Potential.

Authors:  Wafaa A Abd El-Ghany
Journal:  Vet Med Int       Date:  2022-07-16

4.  Comparative Efficacy of Topical Pertmehrin, Crotamiton and Sulfur Ointment in Treatment of Scabies.

Authors:  Celestyna Mila-Kierzenkowska; Alina Woźniak; Ewa Krzyżyńska-Malinowska; Lucyna Kałużna; Roland Wesołowski; Wojciech Poćwiardowski; Marcin Owcarz
Journal:  J Arthropod Borne Dis       Date:  2017-03-14       Impact factor: 1.198

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.